Teva Pharmaceutical Industries Limited (TEVA) CEO Kåre Schultz on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/03/22
Teva Posts Mixed Q1 Earnings, Cuts FY22 Sales Guidance Citing Copaxone Competition, Yet Shares RiseBenzinga • 05/03/22
Teva Announces Settlement with Lupin Resolving AUSTEDO® (deutetrabenazine) Patent DisputeBusiness Wire • 05/02/22
Teva to Host Conference Call to Discuss First Quarter 2022 Financial Results at 8 a.m. ET on May 3, 2022Business Wire • 04/04/22
West Virginia Says J&J, Teva, AbbVie Caused 'Tsunami' Of Opioid Addiction: ReutersBenzinga • 04/04/22
Teva to Present New Analyses of AJOVY® (fremanezumab-vfrm) Injection and AUSTEDO® (deutetrabenazine) Tablets at 2022 American Academy of Neurology Annual MeetingBusiness Wire • 04/01/22
Teva Reaches Agreement With Florida to Settle the State's Opioid-Related ClaimsBusiness Wire • 03/30/22
Teva stock jumps toward longest win streak in 2 years, after Bernstein analyst turns bullishMarket Watch • 03/25/22